THERAPY DOSSIER · th-1491fa194746

Peritoneal M2 macrophages, polarised ex vivo with M-CSF and IL-4/IL-13 (20 ng/mL each)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32004417 ↗2020Reported benefit

Peritoneal M2 macrophage transplantation as a potential cell therapy for enhancing renal repair in acute kidney injury.

MouseIschaemia-reperfusionRenalC57BL/6MaleDirect injection into the renal cortexMacrophage suspension in 50 uL phosphate-buffered saline in…

Model: Renal ischaemia-reperfusion acute kidney injury produced by bilateral renal artery (pedicle) occlusion for 30 min followed by reperfusion

Peritoneal M2 macrophages alleviated renal injury and the inflammatory response after ischaemia-reperfusion injury and promoted proximal tubular epithelial cell proliferation both in vivo and in vitro, supporting M2 macrophage transplantation as a candidate cell therapy for acute kidney injury.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…